CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells

A. Takeshita, N. Yamakage, K. Shinjo, T. Ono, I. Hirano, S. Nakamura, K. Shigeno, T. Tobita, M. Maekawa, H. Kiyoi, T. Naoe, K. Ohnishi, Yoshikazu Sugimoto, R. Ohno

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We studied the effect of CMC-544, the calicheamicin-conjugated anti-CD22 monoclonal antibody, used alone and in combination with rituximab, analyzing the quantitative alteration of target molecules, that is, CD20, CD22, CD55 and CD59, in Daudi and Raji cells as well as in cells obtained from patients with B-cell malignancies (BCM). Antibody inducing direct antiproliferative and apoptotic effect, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) were tested separately. In Daudi and Raji cells, the CDC effect of rituximab significantly increased within 12h following incubation with CMC-544. The levels of CD22 and CD55 were significantly reduced (P<0.001 in both cells) after incubation with CMC-544, but CD20 level remained constant or increased for 12h. Similar results were obtained in cells from 12 patients with BCM. The antiproliferative and apoptotic effect of CMC-544 were greater than that of rituximab. The ADCC of rituximab was not enhanced by CMC-544. Thus, the combination of CMC-544 and rituximab increased the in vitro cytotoxic effect in BCM cells, and sequential administration for 12h proceeded by CMC-544 was more effective. The reduction of CD55 and the preservation of CD20 after incubation with CMC-544 support the rationale for the combined use of CMC-544 and rituximab.

Original languageEnglish
Pages (from-to)1329-1336
Number of pages8
JournalLeukemia
Volume23
Issue number7
DOIs
Publication statusPublished - 2009

Fingerprint

B-Lymphocytes
Antibodies
Inotuzumab Ozogamicin
Neoplasms
Rituximab
Monoclonal Antibodies

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. / Takeshita, A.; Yamakage, N.; Shinjo, K.; Ono, T.; Hirano, I.; Nakamura, S.; Shigeno, K.; Tobita, T.; Maekawa, M.; Kiyoi, H.; Naoe, T.; Ohnishi, K.; Sugimoto, Yoshikazu; Ohno, R.

In: Leukemia, Vol. 23, No. 7, 2009, p. 1329-1336.

Research output: Contribution to journalArticle

Takeshita, A, Yamakage, N, Shinjo, K, Ono, T, Hirano, I, Nakamura, S, Shigeno, K, Tobita, T, Maekawa, M, Kiyoi, H, Naoe, T, Ohnishi, K, Sugimoto, Y & Ohno, R 2009, 'CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells', Leukemia, vol. 23, no. 7, pp. 1329-1336. https://doi.org/10.1038/leu.2009.77
Takeshita, A. ; Yamakage, N. ; Shinjo, K. ; Ono, T. ; Hirano, I. ; Nakamura, S. ; Shigeno, K. ; Tobita, T. ; Maekawa, M. ; Kiyoi, H. ; Naoe, T. ; Ohnishi, K. ; Sugimoto, Yoshikazu ; Ohno, R. / CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. In: Leukemia. 2009 ; Vol. 23, No. 7. pp. 1329-1336.
@article{ef5544df84fc47a1bebdb964ea3c5617,
title = "CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells",
abstract = "We studied the effect of CMC-544, the calicheamicin-conjugated anti-CD22 monoclonal antibody, used alone and in combination with rituximab, analyzing the quantitative alteration of target molecules, that is, CD20, CD22, CD55 and CD59, in Daudi and Raji cells as well as in cells obtained from patients with B-cell malignancies (BCM). Antibody inducing direct antiproliferative and apoptotic effect, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) were tested separately. In Daudi and Raji cells, the CDC effect of rituximab significantly increased within 12h following incubation with CMC-544. The levels of CD22 and CD55 were significantly reduced (P<0.001 in both cells) after incubation with CMC-544, but CD20 level remained constant or increased for 12h. Similar results were obtained in cells from 12 patients with BCM. The antiproliferative and apoptotic effect of CMC-544 were greater than that of rituximab. The ADCC of rituximab was not enhanced by CMC-544. Thus, the combination of CMC-544 and rituximab increased the in vitro cytotoxic effect in BCM cells, and sequential administration for 12h proceeded by CMC-544 was more effective. The reduction of CD55 and the preservation of CD20 after incubation with CMC-544 support the rationale for the combined use of CMC-544 and rituximab.",
author = "A. Takeshita and N. Yamakage and K. Shinjo and T. Ono and I. Hirano and S. Nakamura and K. Shigeno and T. Tobita and M. Maekawa and H. Kiyoi and T. Naoe and K. Ohnishi and Yoshikazu Sugimoto and R. Ohno",
year = "2009",
doi = "10.1038/leu.2009.77",
language = "English",
volume = "23",
pages = "1329--1336",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells

AU - Takeshita, A.

AU - Yamakage, N.

AU - Shinjo, K.

AU - Ono, T.

AU - Hirano, I.

AU - Nakamura, S.

AU - Shigeno, K.

AU - Tobita, T.

AU - Maekawa, M.

AU - Kiyoi, H.

AU - Naoe, T.

AU - Ohnishi, K.

AU - Sugimoto, Yoshikazu

AU - Ohno, R.

PY - 2009

Y1 - 2009

N2 - We studied the effect of CMC-544, the calicheamicin-conjugated anti-CD22 monoclonal antibody, used alone and in combination with rituximab, analyzing the quantitative alteration of target molecules, that is, CD20, CD22, CD55 and CD59, in Daudi and Raji cells as well as in cells obtained from patients with B-cell malignancies (BCM). Antibody inducing direct antiproliferative and apoptotic effect, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) were tested separately. In Daudi and Raji cells, the CDC effect of rituximab significantly increased within 12h following incubation with CMC-544. The levels of CD22 and CD55 were significantly reduced (P<0.001 in both cells) after incubation with CMC-544, but CD20 level remained constant or increased for 12h. Similar results were obtained in cells from 12 patients with BCM. The antiproliferative and apoptotic effect of CMC-544 were greater than that of rituximab. The ADCC of rituximab was not enhanced by CMC-544. Thus, the combination of CMC-544 and rituximab increased the in vitro cytotoxic effect in BCM cells, and sequential administration for 12h proceeded by CMC-544 was more effective. The reduction of CD55 and the preservation of CD20 after incubation with CMC-544 support the rationale for the combined use of CMC-544 and rituximab.

AB - We studied the effect of CMC-544, the calicheamicin-conjugated anti-CD22 monoclonal antibody, used alone and in combination with rituximab, analyzing the quantitative alteration of target molecules, that is, CD20, CD22, CD55 and CD59, in Daudi and Raji cells as well as in cells obtained from patients with B-cell malignancies (BCM). Antibody inducing direct antiproliferative and apoptotic effect, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) were tested separately. In Daudi and Raji cells, the CDC effect of rituximab significantly increased within 12h following incubation with CMC-544. The levels of CD22 and CD55 were significantly reduced (P<0.001 in both cells) after incubation with CMC-544, but CD20 level remained constant or increased for 12h. Similar results were obtained in cells from 12 patients with BCM. The antiproliferative and apoptotic effect of CMC-544 were greater than that of rituximab. The ADCC of rituximab was not enhanced by CMC-544. Thus, the combination of CMC-544 and rituximab increased the in vitro cytotoxic effect in BCM cells, and sequential administration for 12h proceeded by CMC-544 was more effective. The reduction of CD55 and the preservation of CD20 after incubation with CMC-544 support the rationale for the combined use of CMC-544 and rituximab.

UR - http://www.scopus.com/inward/record.url?scp=67650838453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650838453&partnerID=8YFLogxK

U2 - 10.1038/leu.2009.77

DO - 10.1038/leu.2009.77

M3 - Article

C2 - 19369961

AN - SCOPUS:67650838453

VL - 23

SP - 1329

EP - 1336

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -